666 related articles for article (PubMed ID: 17433424)
1. Prognostic factors in pathologic parametrium-positive patients with stage IB-IIB cervical cancer treated by radical surgery and adjuvant therapy.
Kodama J; Seki N; Nakamura K; Hongo A; Hiramatsu Y
Gynecol Oncol; 2007 Jun; 105(3):757-61. PubMed ID: 17433424
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH
Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors.
Uno T; Ito H; Itami J; Yasuda S; Isobe K; Hara R; Sato T; Minoura S; Shigematsu N; Kubo A
Anticancer Res; 2000; 20(3B):2235-9. PubMed ID: 10928184
[TBL] [Abstract][Full Text] [Related]
4. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of prognostic factors in patients with cervical squamous cell carcinoma of stage Ib and IIa].
Chen L; Lü WG; Xie X; Chen HZ; Yu H; Ni XH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):239-42. PubMed ID: 15924669
[TBL] [Abstract][Full Text] [Related]
6. Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer.
Shimada M; Kigawa J; Takahashi M; Minagawa Y; Okada M; Kanamori Y; Itamochi H; Oishi T; Iba T; Terakawa N
Gynecol Oncol; 2004 Jun; 93(3):628-31. PubMed ID: 15196855
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy.
Kodama J; Seki N; Masahiro S; Kusumoto T; Nakamura K; Hongo A; Hiramatsu Y
J Surg Oncol; 2010 Apr; 101(5):413-7. PubMed ID: 20127891
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis of patients with stage Ib-IIb node-positive cervical carcinoma].
Cheng X; Cai SM; Li ZT; Tang MQ; Xue MQ; Zang RY
Ai Zheng; 2003 Nov; 22(11):1219-23. PubMed ID: 14613657
[TBL] [Abstract][Full Text] [Related]
9. Postoperative pelvic radiotherapy for cervical cancer patients with positive parametrial invasion.
Uno T; Ito H; Isobe K; Kaneyasu Y; Tanaka N; Mitsuhashi A; Suzuka K; Yamazawa K; Shigematsu N; Itami J
Gynecol Oncol; 2005 Feb; 96(2):335-40. PubMed ID: 15661218
[TBL] [Abstract][Full Text] [Related]
10. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.
Aoki Y; Sasaki M; Watanabe M; Sato T; Tsuneki I; Aida H; Tanaka K
Gynecol Oncol; 2000 May; 77(2):305-9. PubMed ID: 10785483
[TBL] [Abstract][Full Text] [Related]
11. Early stage cervical cancer: adjuvant treatment in negative lymph node cases.
Sartori E; Tisi G; Chiudinelli F; La Face B; Franzini R; Pecorelli S
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S170-4. PubMed ID: 17765298
[TBL] [Abstract][Full Text] [Related]
12. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma.
Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML
Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma.
Grisaru DA; Covens A; Franssen E; Chapman W; Shaw P; Colgan T; Murphy J; DePetrillo D; Lickrish G; Laframboise S; Rosen B
Cancer; 2003 Apr; 97(8):1904-8. PubMed ID: 12673716
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
Lerouge D; Touboul E; Lefranc JP; Uzan S; Jannet D; Moureau-Zabotto L; Genestie C; Antoine M; Jamali M
Cancer Radiother; 2004 Jun; 8(3):168-77. PubMed ID: 15217584
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
17. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes.
Samlal RA; van der Velden J; Ten Kate FJ; Schilthuis MS; Hart AA; Lammes FB
Cancer; 1997 Oct; 80(7):1234-40. PubMed ID: 9317173
[TBL] [Abstract][Full Text] [Related]
18. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
[TBL] [Abstract][Full Text] [Related]
19. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Zheng M; Huang L; Liu JH; Xiong Y; Li JD; Huang X; He L; Ren YF; Wang HY
J Surg Oncol; 2011 Oct; 104(5):480-5. PubMed ID: 21538358
[TBL] [Abstract][Full Text] [Related]
20. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
